

Review Article

Generation and Applications of Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells

Chengzhu Zhao and Makoto Ikeya 

Department of Clinical Application, Center for iPSC Cell Research and Application, Kyoto University, Kyoto 606-8507, Japan

Correspondence should be addressed to Makoto Ikeya; mikeya@cira.kyoto-u.ac.jp

Received 25 January 2018; Revised 12 June 2018; Accepted 20 June 2018; Published 31 July 2018

Academic Editor: Krisztian Nemeth

Copyright © 2018 Chengzhu Zhao and Makoto Ikeya. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mesenchymal stem cells (MSCs) are adult stem cells with fibroblast-like morphology and isolated from the bone marrow via plastic adhesion. Their multipotency and immunoregulatory properties make MSCs possible therapeutic agents, and an increasing number of publications and clinical trials have highlighted their potential in regenerative medicine. However, the finite proliferative capacity of MSCs limits their scalability and global dissemination as a standardized therapeutic product. Furthermore, adult tissue provenance could constrain accessibility, impinge on cellular potency, and incur greater exposure to disease-causing pathogens based on the donor. These issues could be circumvented by the derivation of MSCs from pluripotent stem cells. In this paper, we review methods that induce and characterize MSCs derived from induced pluripotent stem cells (iPSCs) and introduce MSC applications to disease modeling, pathogenic mechanisms, and drug discovery. We also discuss the potential applications of MSCs in regenerative medicine including cell-based therapies and issues that should be overcome before iPSC-derived MSC therapy will be applied in the clinic.

1. Introduction

Mesenchymal stem cells (MSCs) are derived from the bone marrow, adipose tissue, or other connective tissues. Importantly, they have promise for tissue repair because of their expandability and multipotency. MSCs are able to differentiate into a broad spectrum of end-stage cell types such as osteoblasts, chondrocytes, myocytes, and adipocytes. Many reports have demonstrated that MSCs secrete a wide variety of bioactive molecules that exhibit immunoregulatory and microenvironment modulatory effects at the site of injury. These properties make MSCs as potential candidate for regenerative medicine.

However, MSCs derived from these cell sources have some limitations, including limited cell proliferative capacity and alterations in phenotype and differentiation potential during long-term culture [1]. Moreover, the quality of MSCs varies widely among donors [2–4]. Consequently, despite their potential, in some cases, MSCs have not translated well for the research and treatment of patients. Instead, an inexhaustible and safe source of MSCs is ideal.

MSCs induced from pluripotent stem cells (PSCs), such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), could provide such a source. Both possess properties of infinite growth and differentiation, making it possible to avoid long-term culture as MSCs. PSCs are also compatible with gene-directed enzyme prodrug therapy (GDEPT) or CRISPR/Cas9 and related technologies [5, 6] for gene editing. Moreover, iPSCs can be obtained with minimally invasive procedures and avoid the key ethical controversy surrounding ESCs regarding embryo use [7–9]. They also minimize immunologic problems when autologous or HLA-matched iPSC lines are used [10]. These characteristics enable the study of MSC-related diseases, drug screening using patient cells, and the transplantation of large quantities of cells for cell therapy opening a new avenue for translational medicine.

However, several issues must first be answered before iPSC-derived MSCs (iMSCs) fulfill this potential. For example, the key signals and optimum protocols for effective differentiation and criteria for the evaluation of the clinical quality and safety of iMSCs are still to be

determined. In this article, we describe recent research pertaining to the differentiation methods of MSCs from iPSCs, the application of iMSCs to disease modeling and drug screening, animal experiments using iMSC-based cells for preclinical study, and challenges that should be overcome before clinical application.

2. Derivation of MSCs from iPSCs

The past ten years have seen a great rise in efforts to generate MSCs from PSCs. Multiple protocols exist to derive cells with the features that characterize MSCs. The original strategy to generate MSCs from PSCs involved depriving the culture medium of pluripotent signals, which resulted in spontaneous differentiation to MSCs that mechanically separated from PSCs [11–13]. Although these cells exhibit MSC morphology and express MSC surface markers, the differentiation induction was inefficient. Later, researchers showed that it is possible to obtain MSCs by using a medium supplemented with bFGF [14–16]. These cells are highly similar to MSCs with regard to morphology and expression of markers. However, they have diminished differentiation potential, particularly toward adipogenic lineage [15].

The regulation of signaling that mimics embryonic development is considered necessary to ensure MSCs derived from PSCs exhibit predictable properties and functions [17]. Although the developmental origins of MSCs are not fully understood, somatic lateral plate mesoderm is considered to be the major source of MSCs (LPM in Figure 1(a)) because it gives rise to the majority of the body's adipose and skeletal tissues [18, 19]. Based on better understanding of the critical signals for mesoderm, several reports have shown the induction of mesoderm and then MSCs using known morphogens. For example, Mahmood et al. inhibited TGF β signaling with the use of SB-431542 during PSC differentiation in embryoid body [18]. Sánchez et al. used a similar strategy but this time in cells that grew only in two dimensions (2D) [19]. These protocols were demonstrated to be effective in differentiating PSCs into MSCs, as the derived cells expressed mesenchymal surface markers and possessed multipotency and immune regulation activity.

Neural crest was identified as another developmental origin of MSCs [20, 21]. Simple and efficient methods to generate MSCs through neural crest cell lineage from iPSCs have been established by several groups [22–28]. The activation of canonical Wnt signaling and the prevention of TGF β signaling are common approaches used to obtain a highly enriched induced neural crest cell (iNCC) population. To establish an ideal method with respect to clinical application, feeder-free and serum-free culture should be performed using coating material and chemically defined medium (CDM). Some reported protocols are suitable for these demands [22, 25, 27]. For example, Menendez et al. employed a two-step approach that first dissociated iPSCs into single cells, then cultured them for two weeks in the CDM to achieve feeder-free, serum-free condition, and finally supplemented the culture with Wnt signaling activator and Activin/Nodal/TGF β signaling inhibitor [25]. Mica et al. cultured PSCs in MEF-conditioned hESC media, then

substituted the medium with knockout serum replacement- (KSR-) based medium, and finally replaced KSR gradually with increasing amounts of N2 medium. Next, BMP signaling and Activin/Nodal/TGF β signaling inhibitors were included and then replaced with a Wnt signaling activator [27]. Our group has developed a strong and efficient iMSC generating method using CDM containing TGF β and GSK3 β signaling inhibitors with minimal growth factors [22]. This protocol generated iNCCs (70–80%) independent of the human PSC generation method (viral-integrated or plasmid-episomal). iNCCs can be expanded a long time under conditions of bFGF and EGF supplementation and TGF β inhibition, and our protocol could generate a homogeneous, completely differentiated population of MSCs. Moreover, frozen stocks of both iNCCs and iMSCs can be made (Figure 1(b)) providing greater convenience for future clinical use.

2.1. Characterization of iMSCs. iMSCs exhibit plastic adherence, express MSC surface markers, and can differentiate into osteoblasts, adipocytes, and chondroblasts. These properties satisfy the minimal criteria of human MSCs proposed by the International Society of Cellular Therapy [29, 30]. Genome-wide expression profiles of iMSCs were compared to well-defined MSC types, such as adult bone marrow-derived MSCs (BM-MSCs), and significant overlap of both types in gene expressions has been shown [22, 31–34]. Meanwhile, iMSCs maintained gene expressions and DNA methylation profiles in accordance with the initial donor, except for tissue-specific and age-related DNA methylation profiles [35]. The marker expression pattern in iMSCs was distinct from iPSCs. Namely, the expression of CD-326, Tra-1-60, SSEA-4, and E-cadherin were diminished [29]. These features should be considered before the application of iMSCs to animal experiments and preclinical trials.

When considering the main source for the derivation of iPSCs, it should be noted that human dermal fibroblasts (HDFs) exhibit phenotypic similarity to MSCs. For example, the same surface phenotype (CD73⁺, CD90⁺, and CD105⁺ cell level), immunosuppressive ability [36–39], and even osteo/chondro/adipo differentiation ability [40] between HDFs and MSCs were reported. These properties may interfere with cell identification during iMSC application. Highly similar gene and microRNA expression patterns of HDFs and MSCs were reported, suggesting overlapping phenotypic and functional properties [41].

Because some clinical iPSC lines were derived from HDFs, ways to separate HDFs from HDF-derived iMSCs are necessary to apply these lines. However, at present, there is no reliable marker for HDFs differentiated from HDF-derived iMSCs, but there do exist a number of candidates. TM4SF1 is a surface protein that is highly expressed in various MSC sources but not in fibroblasts [42]. A genome-wide oligonucleotide microarray analysis of HDFs and MSCs might also be beneficial. Additionally, a number of transmembrane protein, tumor, and metastasis-related genes have been found to be upregulated 10-fold in MSCs compared with HDFs, while HDFs show significantly higher surface antibody CD10 levels. Culture conditions




FIGURE 1: Derivation of MSCs from iPSCs. (a) Inducing iMSCs from iPSCs by mimicking embryonic development. During embryonic development, MSCs arise from two major sources: mesoderm and neural crest cells (left). Protocols for the induction include specific signals and morphogens that drives the iPSCs to mesoderm/NCC formation and then generate iMSCs (right). LPM: lateral plate mesoderm. (b) Protocols that induce iMSCs from iPSCs through iNCCs result in a homogeneous mesenchymal cell population without contamination of other cellular phenotypes; therefore, when differentiation is complete, no remnants of undifferentiated cells are found. Frozen stocks can be made to use cells of the same quality in order to evaluate reproducibility.

that induce MSCs to differentiate into osteocytes, adipocytes, and chondrocytes do not induce HDFs to differentiate into any of these lineages [41]. Together, these properties could be used to identify iMSCs.

2.2. iMSC-Based Disease Modeling and Drug Discovery. Clarifying the pathological mechanisms underlying human diseases is important for the discovery of novel therapeutic strategies for genetic diseases. Because of limitations in patient tissue and the lack of appropriate animal models, research on these genetic disorders remains challenging. Cellular disease models using patient-specific iPSCs provide new understanding of these diseases. iMSCs differentiated from patient iPSCs not only act as ideal tools for pathologic research but also provide platforms for drug screening and toxicity testing.

Deyle et al. [43] reported an iPSC model for osteogenesis imperfecta (OI), a genetic bone disorder caused by a dominant mutation in type 1 collagen genes. They generated transplantable patient-specific iMSCs differentiated from OI patient iPSCs in which the collagen mutation was removed. These cells could act as bone-forming cells for the purpose of treating defects in the skeletal tissue of OI patients.

Liu et al. modeled Fanconi anaemia (FA), a rare disease caused by an impaired response to DNA damage, using patient-derived iMSCs. FA-iMSCs showed impairment in maintenance and proliferation, similar to MSCs from *Fancg*-deficient mice [44].

Zhang et al. prepared iMSCs from patients with Hutchinson-Gilford progeria syndrome (HGPS) to study the pathology. HGPS is a segmental premature aging disease that affects mesenchymal lineages and is caused by progerin, a truncated and farnesylated form of Lamin A. HGFP-iMSCs exhibit abnormalities including increased nuclear dysmorphology, DNA damage, and an accumulation of calponin-staining inclusion bodies, which are all properties consistent with fibroblasts isolated from HGPS patients. Compromised viability of HGFP-iMSCs under stress was observed *in vitro* and *in vivo*, especially to hypoxia. Reducing progerin levels by shRNA restored the ability of HGPS-iMSCs to resist hypoxia. Researchers have suggested that progerin toxicity makes HGPS-iMSCs overly sensitive to their hypoxic microenvironment, leading to exhaustion of the MSC pool caused by replacing lost mesenchymal tissue [45]. Cicero et al. performed a high-throughput screening of 2800 small molecules that could inhibit the differentiation of HGPS-iMSCs




FIGURE 2: iMSC-based disease modeling and drug discovery of FOP. iMSCs generated from FOP patient-derived iPSC clones (FOP-iMSC) and gene-corrected (rescued) iPSC clones (resFOP-iPSC) could be applied to *in vitro* disease modeling, drug screening, and *in vivo* drug efficacy evaluation.

towards osteogenic lineage by monitoring alkaline phosphatase activity (ALP). They identified seven compounds that significantly decreased premature osteogenic differentiation, four of which decreased progerin expression [46].

Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease that is characterized by progressive heterotopic ossification (HO) in connective tissues. It is caused by mutations in the *ACVR1* gene, which encodes Activin-A receptor type 1, an important protein in the bone morphogenetic protein (BMP) pathway. Our group [47, 48] generated FOP patient-derived iPSC clones and gene-corrected (rescued) iPSC clones (resFOP-iPSC). iMSCs were induced from both iPSC clones through neural crest cell lineage. FOP-iMSCs exhibited augmented chondrogenic ability and enhanced activity of the SMAD1/5/8 pathway compared to resFOP-iMSCs, successfully recapitulating the disease phenotype. Using these cells, we screened TGF β superfamily ligands that could specifically activate BMP signaling through FOP-*ACVR1* by a luciferase reporter (BRE-Luc) assay and found a new FOP mechanism. Activin-A, a TGF β signal transducer, evokes BMP signaling activation via FOP-*ACVR1*. To develop an *in vivo* evaluation system, FOP- and resFOP-iMSCs were transplanted together with Activin-A-expressing C3H10T1/2 cells into the skeletal muscle of immunodeficient mice. HO was developed at the transplanted site after six weeks, suggesting Activin-A induces extraskeletal bone formation in FOP [49].

To reveal the molecular mechanisms of the enhanced chondrogenesis evoked by Activin-A and to discover potential therapeutic targets, a high-throughput screening (HTS) system was established using FOP-iMSCs. From the screening of nearly 7000 small-molecule compounds, the mTOR signaling pathway was identified as important in the excessive chondrogenesis seen in FOP-iMSCs. Rapamycin, a commonly used mTOR inhibitor and commercially available

drug, repressed HO in FOP-iMSC-transplanted mouse extensively. According to a DNA microarray assay, ENPP2 (also known as autotaxin) was indicated to act upstream of mTOR signaling, upregulating the chondrogenesis activity of FOP-iMSCs in response to Activin-A [50].

The FOP study shows that iMSC-based hereditary disease models and drug discovery platforms can reliably reproduce disease phenotypes and offer tremendous advantage for exploring drug candidates and critical disease mechanisms, accelerating the development of novel therapies (Figure 2).

2.3. iMSC-Based Experimental Therapies and Challenges. As the origin of iMSC derivation, iPSCs can be obtained from any adult tissue source and used to generate an abundance of iMSCs at low passage [51]. Furthermore, the abilities of iMSCs to differentiate into multiple tissues, produce a broad variety of cytokines and paracrine factors, regulate immune response, secrete exosomes, and exhibit mitochondrial transfer function suggest they could be potential cell sources for therapeutic purposes.

A number of animal studies using iMSCs have shown significant benefits on tissue regeneration and repair. iMSCs promote periodontal regeneration and new mineralized tissue formation when implanted into rat periodontal defect models [29]. The transplantation of iMSC-induced osteoblast into the calvarial defects of mice was found to support bone formation at the defect site [46]. iMSCs also exert stem cell factor-dependent recovery of cigarette smoke-induced apoptosis/proliferation imbalance in airway cells [52]. After being implanted into an ischemic site in mouse hindlimb, iMSCs significantly attenuated the physiological status to a degree superior than adult BM-MSCs [53]. The repair ability of iMSCs in myocardial infarction, cigarette smoke-induced cardiac remodeling, and dysfunction mouse model has also been observed [54, 55]. Similar to the ischemia in hindlimb,

the cardiac wound repairing and proangiogenic potency of iMSCs were superior to those of BM-MSCs and umbilical cord blood-derived MSCs [56]. The greater therapeutic potential of iMSCs may be due to their superior survival and engraftment (for more than 5 weeks) after transplantation [52].

In addition, iMSCs are safe and efficient as immune modulators in both inflammation and autoimmunity diseases, presumably due to their ability to suppress abnormal immune response [57–59]. An *in vitro* study indicated that iMSCs remarkably impair the proliferation and cytolytic function of NK cells. Again, this effect by iMSCs was stronger than that of BM-MSCs, suggesting iMSCs could be a useful therapeutic choice to inhibit allograft rejection [38]. After transplantation into streptozotocin-diabetic mice, iMSCs ameliorated diabetic polyneuropathy (DNP) [60].

Exosomes assembled from iMSCs exhibit therapeutic potential in several animal disease models [56, 61]. Recent studies report that tissue repairing ability of iMSC via mitochondrial transfer mechanism exhibit superior effect on the mouse model of anthracycline-induced cardiomyopathy and cigarette smoke-induced lung damage compared with BM-MSCs [62, 63].

There are a large number of clinical trials using MSCs in various diseases, including cardiovascular diseases, hepatic diseases, neurological disorders, and autoimmune diseases (<http://ClinicalTrials.gov>). However, before iMSCs can serve as an alternative source of MSCs in the clinic, several obstacles must be overcome [64]. Because they are derived from iPSCs, iMSCs need to be carefully tested for alterations in oncologic genes [65]. The classic method to induce iPSCs involved the use of a retrovirus to overexpress *c-Myc*, a protooncogene that increases reprogramming efficiency by inhibiting the tumor repressor gene *p53*, which can increase the probability of tumor formation. Safe and effective factors along with nonviral gene delivery systems are expected to enhance the safety profile of iMSCs for clinical application [66–70]. Furthermore, the purity and quality of the iMSCs must be considered. Sorting iMSCs by the positive expression of MSC markers and the negative expression of pluripotency markers and testing the potential of oncogenesis on animal models should be performed before advancing iMSCs to the clinic [71].

3. Conclusion and Future Perspectives

iMSCs are a potentially abundant source of MSCs for disease modeling, drug discovery, and regenerative medicine [27]. To further advance iMSC-based therapeutic applicability and minimize the risk of immunoreaction after administration, it is necessary to optimize iPSC and iMSC production protocols. Removing oncogenic or other unstable factors and employing xeno-free culture condition at the reprogramming and differentiation induction step are necessary. The combination of new approaches into iMSC platforms, such as 3D organoid and gene editing technologies, might render iMSCs more valuable for further clinical application.

Conflicts of Interest

The authors declare that they have no conflict of interest.

Acknowledgments

The authors thank Dr. P. Karagiannis for reading the manuscript and members of the M.I. Laboratories for their kind support. This work was supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS) (16H05447, 18H02977), the Japan-Korea Basic Scientific Cooperation Program (JSPS and National Research Foundation of Korea), the Acceleration Program for Intractable Diseases Research utilizing Disease-specific iPSCs from the Japan Agency for Medical Research and Development (AMED), the Core Center for iPSC Cell Research of the Research Center Network for the Realization of Regenerative Medicine (the Japan Science and Technology Agency (JST)/AMED), and a grant from the iPSC Cell Research Fund. Chengzhu Zhao was also supported by Grant-in-Aid for Young Scientists B from JSPS (17K15617).

References

- [1] W. Wagner, P. Horn, M. Castoldi et al., “Replicative senescence of mesenchymal stem cells: a continuous and organized process,” *PLoS One*, vol. 3, no. 5, article e2213, 2008.
- [2] J. D. Kretlow, Y. Q. Jin, W. Liu et al., “Donor age and cell passage affects differentiation potential of murine bone marrow-derived stem cells,” *BMC Cell Biology*, vol. 9, no. 1, p. 60, 2008.
- [3] W. Wagner, S. Bork, P. Horn et al., “Aging and replicative senescence have related effects on human stem and progenitor cells,” *PLoS One*, vol. 4, no. 6, article e5846, 2009.
- [4] Y. Xin, Y. M. Wang, H. Zhang et al., “Aging adversely impacts biological properties of human bone marrow-derived mesenchymal stem cells: implications for tissue engineering heart valve construction,” *Artificial Organs*, vol. 34, no. 3, pp. 215–222, 2010.
- [5] J. A. Doudna and E. Charpentier, “Genome editing. The new frontier of genome engineering with CRISPR-Cas9,” *Science*, vol. 346, no. 6213, p. 1258096, 2014.
- [6] R. Peng, G. Lin, and J. Li, “Potential pitfalls of CRISPR/Cas9-mediated genome editing,” *The FEBS Journal*, vol. 283, no. 7, pp. 1218–1231, 2016.
- [7] K. Takahashi and S. Yamanaka, “Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors,” *Cell*, vol. 126, no. 4, pp. 663–676, 2006.
- [8] K. Takahashi, K. Tanabe, M. Ohnuki et al., “Induction of pluripotent stem cells from adult human fibroblasts by defined factors,” *Cell*, vol. 131, no. 5, pp. 861–872, 2007.
- [9] J. Yu, M. A. Vodyanik, K. Smuga-Otto et al., “Induced pluripotent stem cell lines derived from human somatic cells,” *Science*, vol. 318, no. 5858, pp. 1917–1920, 2007.
- [10] C. de Rham and J. Villard, “Potential and limitation of HLA-based banking of human pluripotent stem cells for cell therapy,” *Journal of Immunology Research*, vol. 2014, Article ID 518135, 6 pages, 2014.
- [11] E. N. Olivier, A. C. Rybicki, and E. E. Bouhassira, “Differentiation of human embryonic stem cells into bipotent mesenchymal stem cells,” *Stem Cells*, vol. 24, no. 8, pp. 1914–1922, 2006.

- [12] N. S. Hwang, S. Varghese, H. J. Lee et al., "In vivo commitment and functional tissue regeneration using human embryonic stem cell-derived mesenchymal cells," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 52, pp. 20641–20646, 2008.
- [13] K. Hynes, D. Menicanin, K. Mrozik, S. Gronthos, and P. M. Bartold, "Generation of functional mesenchymal stem cells from different induced pluripotent stem cell lines," *Stem Cells and Development*, vol. 23, no. 10, pp. 1084–1096, 2014.
- [14] C. Karlsson, K. Emanuelsson, F. Wessberg et al., "Human embryonic stem cell-derived mesenchymal progenitors—potential in regenerative medicine," *Stem Cell Research*, vol. 3, no. 1, pp. 39–50, 2009.
- [15] N. L. Boyd, K. R. Robbins, S. K. Dhara, F. D. West, and S. L. Stice, "Human embryonic stem cell-derived mesoderm-like epithelium transitions to mesenchymal progenitor cells," *Tissue Engineering Part A*, vol. 15, no. 8, pp. 1897–1907, 2009.
- [16] Q. Lian, Y. Zhang, X. Liang, F. Gao, and H. F. Tse, "Directed differentiation of human-induced pluripotent stem cells to mesenchymal stem cells," in *Mesenchymal Stem Cells. Methods in Molecular Biology vol 1416*, M. Gnecci, Ed., pp. 289–298, Humana Press, New York, NY, USA, 2016.
- [17] C. D. Luzzani and S. G. Miriuka, "Pluripotent stem cells as a robust source of mesenchymal stem cells," *Stem Cell Reviews and Reports*, vol. 13, no. 1, pp. 68–78, 2017.
- [18] A. Mahmood, L. Harkness, H. D. Schröder, B. M. Abdallah, and M. Kassem, "Enhanced differentiation of human embryonic stem cells to mesenchymal progenitors by inhibition of TGF- β /actin/nodal signaling using SB-431542," *Journal of Bone and Mineral Research*, vol. 25, no. 6, pp. 1216–1233, 2010.
- [19] L. Sánchez, I. Gutierrez-Aranda, G. Ligerio et al., "Enrichment of human ESC-derived multipotent mesenchymal stem cells with immunosuppressive and anti-inflammatory properties capable to protect against experimental inflammatory bowel disease," *Stem Cells*, vol. 29, no. 2, pp. 251–262, 2011.
- [20] Y. Takashima, T. Era, K. Nakao et al., "Neuroepithelial cells supply an initial transient wave of MSC differentiation," *Cell*, vol. 129, no. 7, pp. 1377–1388, 2007.
- [21] S. Morikawa, Y. Mabuchi, K. Niibe et al., "Development of mesenchymal stem cells partially originate from the neural crest," *Biochemical and Biophysical Research Communications*, vol. 379, no. 4, pp. 1114–1119, 2009.
- [22] M. Fukuta, Y. Nakai, K. Kirino et al., "Derivation of mesenchymal stromal cells from pluripotent stem cells through a neural crest lineage using small molecule compounds with defined media," *PLoS One*, vol. 9, no. 12, article e112291, 2014.
- [23] K. Umeda, H. Oda, Q. Yan et al., "Long-term expandable SOX9⁺ chondrogenic ectomesenchymal cells from human pluripotent stem cells," *Stem Cell Reports*, vol. 4, no. 4, pp. 712–726, 2015.
- [24] L. Menendez, M. J. Kulik, A. T. Page et al., "Directed differentiation of human pluripotent cells to neural crest stem cells," *Nature Protocols*, vol. 8, no. 1, pp. 203–212, 2013.
- [25] L. Menendez, T. A. Yatskevych, P. B. Antin, and S. Dalton, "Wnt signaling and a Smad pathway blockade direct the differentiation of human pluripotent stem cells to multipotent neural crest cells," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 108, no. 48, pp. 19240–19245, 2011.
- [26] S. M. Chambers, C. A. Fasano, E. P. Papapetrou, M. Tomishima, M. Sadelain, and L. Studer, "Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling," *Nature Biotechnology*, vol. 27, no. 3, pp. 275–280, 2009.
- [27] Y. Mica, G. Lee, S. M. Chambers, M. J. Tomishima, and L. Studer, "Modeling neural crest induction, melanocyte specification, and disease-related pigmentation defects in hESCs and patient-specific iPSCs," *Cell Reports*, vol. 3, no. 4, pp. 1140–1152, 2013.
- [28] C. Milet and A. H. Monsoro-Burq, "Embryonic stem cell strategies to explore neural crest development in human embryos," *Developmental Biology*, vol. 366, no. 1, pp. 96–99, 2012.
- [29] K. Hynes, D. Menicanin, J. Han et al., "Mesenchymal stem cells from iPSCs facilitate periodontal regeneration," *Journal of Dental Research*, vol. 92, no. 9, pp. 833–839, 2013.
- [30] C. Luzzani, G. Neiman, X. Garate et al., "A therapy-grade protocol for differentiation of pluripotent stem cells into mesenchymal stem cells using platelet lysate as supplement," *Stem Cell Research & Therapy*, vol. 6, no. 1, p. 6, 2015.
- [31] T. Barberi, L. M. Willis, N. D. Socci, and L. Studer, "Derivation of multipotent mesenchymal precursors from human embryonic stem cells," *PLoS Medicine*, vol. 2, no. 6, article e161, 2005.
- [32] A. M. Billing, H. Ben Hamidane, S. S. Dib et al., "Comprehensive transcriptomic and proteomic characterization of human mesenchymal stem cells reveals source specific cellular markers," *Scientific Reports*, vol. 6, no. 1, pp. 507–515, 2016.
- [33] D. Sheyn, S. Ben-David, G. Shapiro et al., "Human induced pluripotent stem cells differentiate into functional mesenchymal stem cells and repair bone defects," *Stem Cells Translational Medicine*, vol. 5, no. 11, pp. 1447–1460, 2016.
- [34] S. Diederichs and R. S. Tuan, "Functional comparison of human-induced pluripotent stem cell-derived mesenchymal cells and bone marrow-derived mesenchymal stromal cells from the same donor," *Stem Cells and Development*, vol. 23, no. 14, pp. 1594–1610, 2014.
- [35] Q. Lian, Y. Zhang, J. Zhang et al., "Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice," *Circulation*, vol. 121, no. 9, pp. 1113–1123, 2010.
- [36] M. A. Haniffa, M. P. Collin, C. D. Buckley, and F. Dazzi, "Mesenchymal stem cells: the fibroblasts' new clothes?," *Haematologica*, vol. 94, no. 2, pp. 258–263, 2009.
- [37] S. Jones, N. Horwood, A. Cope, and F. Dazzi, "The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells," *Journal of Immunology*, vol. 179, no. 5, pp. 2824–2831, 2007.
- [38] Y. Shimabukuro, S. Murakami, and H. Okada, "Interferon-gamma-dependent immunosuppressive effects of human gingival fibroblasts," *Immunology*, vol. 76, no. 2, pp. 344–347, 1992.
- [39] M. Krampera, L. Cosmi, R. Angeli et al., "Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells," *Stem Cells*, vol. 24, no. 2, pp. 386–398, 2006.
- [40] J. P. E. Junker, P. Sommar, M. Skog, H. Johnson, and G. Kratz, "Adipogenic, chondrogenic and osteogenic differentiation of clonally derived human dermal fibroblasts," *Cells, Tissues, Organs*, vol. 191, no. 2, pp. 105–118, 2010.

- [41] S. Bae, J. H. Ahn, C. W. Park et al., "Gene and microRNA expression signatures of human mesenchymal stromal cells in comparison to fibroblasts," *Cell and Tissue Research*, vol. 335, no. 3, pp. 565–573, 2009.
- [42] S. Bae, S. H. Shim, C. W. Park et al., "Combined omics analysis identifies transmembrane 4 L6 family member 1 as a surface protein marker specific to human mesenchymal stem cells," *Stem Cells and Development*, vol. 20, no. 2, pp. 197–203, 2011.
- [43] D. R. Deyle, I. F. Khan, G. Ren et al., "Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs," *Molecular Therapy*, vol. 20, no. 1, pp. 204–213, 2012.
- [44] G. H. Liu, K. Suzuki, M. Li et al., "Modelling Fanconi anemia pathogenesis and therapeutics using integration-free patient-derived iPSCs," *Nature Communications*, vol. 5, no. 1, p. 4330, 2014.
- [45] J. Zhang, Q. Lian, G. Zhu et al., "A human iPSC model of Hutchinson Gilford progeria reveals vascular smooth muscle and mesenchymal stem cell defects," *Cell Stem Cell*, vol. 8, no. 1, pp. 31–45, 2011.
- [46] A. Lo Cicero, A. L. Jaskowiak, A. L. Egesipe et al., "A high throughput phenotypic screening reveals compounds that counteract premature osteogenic differentiation of HGPS iPS-derived mesenchymal stem cells," *Scientific Reports*, vol. 6, no. 1, p. 34798, 2016.
- [47] Y. Matsumoto, Y. Hayashi, C. R. Schlieve et al., "Induced pluripotent stem cells from patients with human fibrodysplasia ossificans progressiva show increased mineralization and cartilage formation," *Orphanet Journal of Rare Diseases*, vol. 8, no. 1, p. 190, 2013.
- [48] Y. Matsumoto, M. Ikeya, K. Hino et al., "New protocol to optimize iPS cells for genome analysis of fibrodysplasia ossificans progressiva," *Stem Cells*, vol. 33, no. 6, pp. 1730–1742, 2015.
- [49] K. Hino, M. Ikeya, K. Horigome et al., "Neofunction of ACVR1 in fibrodysplasia ossificans progressiva," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 112, no. 50, pp. 15438–15443, 2015.
- [50] K. Hino, K. Horigome, M. Nishio et al., "Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva," *The Journal of Clinical Investigation*, vol. 127, no. 9, pp. 3339–3352, 2017.
- [51] J. Frobel, H. Hemeda, M. Lenz et al., "Epigenetic rejuvenation of mesenchymal stromal cells derived from induced pluripotent stem cells," *Stem Cell Reports*, vol. 3, no. 3, pp. 414–422, 2014.
- [52] X. Li, Y. Zhang, Y. Liang et al., "iPSC-derived mesenchymal stem cells exert SCF-dependent recovery of cigarette smoke-induced apoptosis/proliferation imbalance in airway cells," *Journal of Cellular and Molecular Medicine*, vol. 21, no. 2, pp. 265–277, 2017.
- [53] Q. Miao, W. Shim, N. Tee et al., "iPSC-derived human mesenchymal stem cells improve myocardial strain of infarcted myocardium," *Journal of Cellular and Molecular Medicine*, vol. 18, no. 8, pp. 1644–1654, 2014.
- [54] Y. Zhang, X. Liang, S. Liao et al., "Potent paracrine effects of human induced pluripotent stem cell-derived mesenchymal stem cells attenuate doxorubicin-induced cardiomyopathy," *Scientific Reports*, vol. 5, no. 1, article 11235, 2015.
- [55] Y. Liang, X. Li, Y. Zhang et al., "Induced pluripotent stem cells-derived mesenchymal stem cells attenuate cigarette smoke-induced cardiac remodeling and dysfunction," *Frontiers in Pharmacology*, vol. 8, p. 501, 2017.
- [56] J. Zhang, J. Guan, X. Niu et al., "Exosomes released from human induced pluripotent stem cells-derived MSCs facilitate cutaneous wound healing by promoting collagen synthesis and angiogenesis," *Journal of Translational Medicine*, vol. 13, no. 1, p. 49, 2015.
- [57] L. Ferrer, E. A. Kimbrel, A. Lam et al., "Treatment of perianal fistulas with human embryonic stem cell-derived mesenchymal stem cells: a canine model of human fistulizing Crohn's disease," *Regenerative Medicine*, vol. 11, no. 1, pp. 33–43, 2016.
- [58] Q. Hao, Y. G. Zhu, A. Monsel et al., "Study of bone marrow and embryonic stem cell-derived human mesenchymal stem cells for treatment of *Escherichia coli* endotoxin-induced acute lung injury in mice," *Stem Cells Translational Medicine*, vol. 4, no. 7, pp. 832–840, 2015.
- [59] Y. Q. Sun, Y. Zhang, X. Li et al., "Insensitivity of human iPSC cells-derived mesenchymal stem cells to interferon- γ -induced HLA expression potentiates repair efficiency of hind limb ischemia in immune humanized NOD scid gamma mice," *Stem Cells*, vol. 33, no. 12, pp. 3452–3467, 2015.
- [60] T. Himeno, H. Kamiya, K. Naruse et al., "Mesenchymal stem cell-like cells derived from mouse induced pluripotent stem cells ameliorate diabetic polyneuropathy in mice," *BioMed Research International*, vol. 2013, Article ID 259187, 12 pages, 2013.
- [61] X. Qi, J. Zhang, H. Yuan et al., "Exosomes secreted by human-induced pluripotent stem cell-derived mesenchymal stem cells repair critical-sized bone defects through enhanced angiogenesis and osteogenesis in osteoporotic rats," *International Journal of Biological Sciences*, vol. 12, no. 7, pp. 836–849, 2016.
- [62] Y. Zhang, Z. Yu, D. Jiang et al., "iPSC-MSCs with high intrinsic MIRO1 and sensitivity to TNF- α yield efficacious mitochondrial transfer to rescue anthracycline-induced cardiomyopathy," *Stem Cell Reports*, vol. 7, no. 4, pp. 749–763, 2016.
- [63] X. Li, Y. Zhang, S. C. Yeung et al., "Mitochondrial transfer of induced pluripotent stem cell-derived mesenchymal stem cells to airway epithelial cells attenuates cigarette smoke-induced damage," *American Journal of Respiratory Cell and Molecular Biology*, vol. 51, no. 3, pp. 455–465, 2014.
- [64] E. Neofytou, C. G. O'Brien, L. A. Couture, and J. C. Wu, "Hurdles to clinical translation of human induced pluripotent stem cells," *The Journal of Clinical Investigation*, vol. 125, no. 7, pp. 2551–2557, 2015.
- [65] R. J. Lund, E. Narva, and R. Lahesmaa, "Genetic and epigenetic stability of human pluripotent stem cells," *Nature Reviews Genetics*, vol. 13, no. 10, pp. 732–744, 2012.
- [66] J. Yu, K. Hu, K. Smuga-Otto et al., "Human induced pluripotent stem cells free of vector and transgene sequences," *Science*, vol. 324, no. 5928, pp. 797–801, 2009.
- [67] I. M. Fang, C. M. Yang, C. H. Yang, S. H. Chiou, and M. S. Chen, "Transplantation of induced pluripotent stem cells without C-Myc attenuates retinal ischemia and reperfusion injury in rats," *Experimental Eye Research*, vol. 113, pp. 49–59, 2013.
- [68] K. Okita, N. Nagata, and S. Yamanaka, "Immunogenicity of induced pluripotent stem cells," *Circulation Research*, vol. 109, no. 7, pp. 720–721, 2011.
- [69] D. Kim, C. H. Kim, J. I. Moon et al., "Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins," *Cell Stem Cell*, vol. 4, no. 6, pp. 472–476, 2009.

- [70] M. Nakagawa, N. Takizawa, M. Narita, T. Ichisaka, and S. Yamanaka, "Promotion of direct reprogramming by transformation-deficient Myc," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 32, pp. 14152–14157, 2010.
- [71] Y. Shi, H. Inoue, J. C. Wu, and S. Yamanaka, "Induced pluripotent stem cell technology: a decade of progress," *Nature Reviews Drug Discovery*, vol. 16, no. 2, pp. 115–130, 2017.